The outcome of antiretroviral combination therapy depends on many factors involving host, virus, and drugs. We investigate prediction of treatment response from the applied drug combination and the genetic constellation of the virus population at baseline. The virus's evolutionary potential for escaping from drug pressure is explored as an additional predictor.
Methods
We compare different encodings of the viral genotype and antiretroviral regimen including phenotypic and evolutionary information, namely predicted phenotypic drug resistance, activity of the regimen estimated from sequence space search, the genetic barrier to drug resistance, and the genetic progression score. These features were evaluated in the context of different statistical learning procedures applied to the binary classification task of predicting virological response. Classifier performance was evaluated using cross-validation and receiver operating characteristic curves on 6,337 observed treatment change episodes from the Stanford HIV Drug Resistance Database and a large US clinic-based patient population.
Results
We find that the choice of appropriate features affects predictive performance more profoundly than the choice of the statistical learning method. Application of the genetic barrier to drug resistance, which combines phenotypic and evolutionary information, outperformed the genetic progression score, which uses exclusively evolutionary knowledge. The benefit of phenotypic information in predicting virological response was confirmed by using predicted fold changes in drug susceptibility. Moreover, genetic barrier and predicted phenotypic drug resistance were found to be the best encodings across all datasets and statistical learning methods examined.
Availability
THEO (THErapy Optimizer), a prototypical implementation of the best performing approach, is freely available for research purposes athttp://www.geno2pheno.org.
References
1.
ReevesJ.D., PieferA.J.Emerging drug targets for antiretroviral therapy.Drugs2005; 65: 1747–1766.
2.
GrabarS., Le MoingV., GoujardC., LeportC., KazatchkineM.D., CostagliolaD.Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.Ann Intern Med2000; 133: 401–410.
3.
ClavelF., HanceA.J.HIV drug resistance.N Engl J Med2004; 350: 1023–1035.
4.
DybulM., FauciA.S., BartlettJ.G., KaplanJ.E., PauA.K.Panel on Clinical Practices for Treatment of HIV Infection, Guidelines for the Use of Antiretroviral Agents in HIV-1–Infected Adults and Adolescents.Ann Intern Med2002; 137: 381–433.
5.
JiangH., DeeksS.G., KuritzkesD.R., LallemantM., KatzensteinD., AlbrechtM.Assessing resistance costs of antiretroviral therapies via measures of future drug options.J Infect Dis2003; 188: 1001–1008.
6.
WangD., LarderB.A., RevellA., HarriganR., MontanerJ.A neural network model using clinical cohort data accurately predicts virological response and identifies regimens with increased probability of success in treatment failures.Antiv Ther2003; 8: U99–U99.
7.
ProsperiM., Di GiambenedettoS., TrottaM.P., CingolaniA., RuizL., BaxterJ.D.A fuzzy relational system trained by genetic algorithms and HIV-1 resistance genotypes/virological response data from prospective studies usefully predicts treatment outcomes.Antiv Ther2004; 9: U89–U89.
8.
ProsperiM., ZazziM., PernoC.F., Di GiambenedettoS., BaxterJ., RuizL.‘Common law’ applied to treatment decisions for drug resistant HIV.Antiv Ther2005; 10: S62–S62.
BeerenwinkelN., DaumerM., SingT., RahnenfuhrerJ., LengauerT., SelbigJ.Estimating HIV evolutionary pathways and the genetic barrier to drug resistance.J Infect Dis2005; 191: 1953–1960.
13.
RahnenfuhrerJ., BeerenwinkelN., SchulzW.A., HartmannC., von DeimlingA., WullichB.Estimating cancer survival and clinical outcome based on genetic tumor progression scores.Bioinformatics2005; 21: 2438–2446.
14.
LarderB.A., WangD., RevellA., LaneC.Neural network model identified potentially effective drug combinations for patients failing salvage therapy.2nd IAS Conference on HIV Pathogenesis and Treatment 13–17 July 2003, Paris, France. Poster LB39.
15.
WalterH., SchmidtB., KornK., VandammeA.M., HarrerT., UberlaK.Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.J Clin Virol1999; 13: 71–80.
16.
JohnsonV.A., Brun-VezinetF., ClotetB., ConwayB., KuritzkesD.R., PillayD.Update of the drug resistance mutations in HIV-1: Fall 2005.Top HIV Med2005; 13: 125–131.
17.
BeerenwinkelN., RahnenfuhrerJ., KaiserR., HoffmannD., SelbigJ., LengauerT.Mtreemix: a software package for learning and using mixture models of mutagenetic trees.Bioinformatics2005; 21: 2106–2107.
BeerenwinkelN.The evolutionary potential of HIV predicts response to antiretroviral therapy. Workshop on Quantitative Methods for Research on Antiviral Resistance. 11–12 May, 2006, Boston, MA, USA.
